Rebleeding after initial endoscopic hemostasis in peptic ulcer disease

Endoscopic hemostasis is the first-line treatment for upper gastrointestinal bleeding (UGIB). Although several factors are known to be risk factors for rebleeding, little is known about the use of antithrombotics. We tried to verify whether the use of antithrombotics affects rebleeding rate after a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2014, 29(10), 193, pp.1411-1415
Main Authors: Hong, Mi Jin, Lee, Sun-Young, Kim, Jeong Hwan, Sung, In-Kyung, Park, Hyung Seok, Shim, Chan Sup, Jin, Choon Jo
Format: Article
Language:English
Subjects:
Antithrombins - therapeutic use
Aspirin - adverse effects
Female
Gastrointestinal Hemorrhage - drug therapy
Gastrointestinal Hemorrhage - surgery
Hemorrhage - drug therapy
Hemostasis, Endoscopic - methods
Humans
Male
Middle Aged
Original
Peptic Ulcer - surgery
Recurrence
Upper Gastrointestinal Tract - pathology
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endoscopic hemostasis is the first-line treatment for upper gastrointestinal bleeding (UGIB). Although several factors are known to be risk factors for rebleeding, little is known about the use of antithrombotics. We tried to verify whether the use of antithrombotics affects rebleeding rate after a successful endoscopic hemostasis for peptic ulcer disease (PUD). UGIB patients who underwent successful endoscopic hemostasis were included. Rebleeding was diagnosed when the previously treated lesion bled again within 30 days of the initial episode. Of 522 UGIB patients with PUD, rebleeding occurred in 93 patients (17.8%). The rate of rebleeding was higher with aspirin medication (P=0.006) and after a long endoscopic hemostasis (P
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2014.29.10.1411